These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39311475)

  • 1. Synthesis, molecular modelling, and biological evaluation of novel quinoxaline derivatives for treating type II diabetes.
    Alasmary FAS; Abdullah DA; Masand VH; Ben Bacha A; Omar Ebeid AM; El-Araby ME; Alafeefy AM
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2395985. PubMed ID: 39311475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New quinoxalinone inhibitors targeting secreted phospholipase A2 and α-glucosidase.
    Alasmary FAS; Alnahdi FS; Ben Bacha A; El-Araby AM; Moubayed N; Alafeefy AM; El-Araby ME
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):1143-1151. PubMed ID: 28856929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing benzenesulfonamide-thiazolidinone hybrids as multitarget directed ligands for efficient control of type 2 diabetes mellitus through targeting the enzymes: α-glucosidase and carbonic anhydrase II.
    Gamal MA; Fahim SH; Giovannuzzi S; Fouad MA; Bonardi A; Gratteri P; Supuran CT; Hassan GS
    Eur J Med Chem; 2024 May; 271():116434. PubMed ID: 38653067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting
    Gohar NA; Fayed EA; A Ammar Y; A Abu Ali O; Ragab A; Mahfoz AM; Abusaif MS
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2367128. PubMed ID: 38913598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unveiling anti-diabetic potential of new thiazole-sulfonamide derivatives: Design, synthesis, in vitro bio-evaluation targeting DPP-4, α-glucosidase, and α-amylase with in-silico ADMET and docking simulation.
    Khamees Thabet H; Ammar YA; Imran M; Hamdy Helal M; Ibrahim Alaqel S; Alshehri A; Ash Mohd A; Abusaif MS; Ragab A
    Bioorg Chem; 2024 Oct; 151():107671. PubMed ID: 39067419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel tetrahydrobenzo[b]thiophen-2-yl)urea derivatives as novel α-glucosidase inhibitors: Synthesis, kinetics study, molecular docking, and in vivo anti-hyperglycemic evaluation.
    Xie HX; Zhang J; Li Y; Zhang JH; Liu SK; Zhang J; Zheng H; Hao GZ; Zhu KK; Jiang CS
    Bioorg Chem; 2021 Oct; 115():105236. PubMed ID: 34411978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new 2-phenyl-1H-benzo[d]imidazole core-based potent α-glucosidase inhibitors: Synthesis, kinetic study, molecular docking, and in vivo anti-hyperglycemic evaluation.
    Li Y; Zhang JH; Xie HX; Ge YX; Wang KM; Song ZL; Zhu KK; Zhang J; Jiang CS
    Bioorg Chem; 2021 Dec; 117():105423. PubMed ID: 34717239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Explore new quinoxaline pharmacophore tethered sulfonamide fragments as in vitro α-glucosidase, α-amylase, and acetylcholinesterase inhibitors with ADMET and molecular modeling simulation.
    Ragab A; Salem MA; Ammar YA; Aboulthana WM; Helal MH; Abusaif MS
    Drug Dev Res; 2024 Jun; 85(4):e22216. PubMed ID: 38831547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase.
    Riaz S; Khan IU; Bajda M; Ashraf M; Qurat-Ul-Ain ; Shaukat A; Rehman TU; Mutahir S; Hussain S; Mustafa G; Yar M
    Bioorg Chem; 2015 Dec; 63():64-71. PubMed ID: 26451651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new anti-diabetic potential agents based on paracetamol incorporating sulfa-drugs: Design, synthesis, α-amylase, and α-glucosidase inhibitors with molecular docking simulation.
    Khamees Thabet H; Ragab A; Imran M; Helal MH; Ibrahim Alaqel S; Alshehri A; Ash Mohd A; Rakan Alshammari M; S Abusaif M; A Ammar Y
    Eur J Med Chem; 2024 Sep; 275():116589. PubMed ID: 38878516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation, and molecular modelling of novel quinoxaline-isoxazole hybrid as anti-hyperglycemic.
    Phongphane L; Mohd Radzuan SN; Abu Bakar MH; Che Omar MT; Supratman U; Harneti D; A Wahab H; Azmi MN
    Comput Biol Chem; 2023 Oct; 106():107938. PubMed ID: 37542847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel acyl hydrazide derivatives of polyhydroquinoline as potent anti-diabetic and anti-glycating agents: Synthesis, in vitro α-amylase, α-glucosidase inhibition and anti-glycating activity with molecular docking insights.
    Ur Rahman S; Alam A; Parveen Z; Zainab ; Assad M; Adnan Ali Shah S; Rafiq H; Ayaz M; Latif A; Naveed Umar M; Ali M; Ahmad M
    Bioorg Chem; 2024 Sep; 150():107501. PubMed ID: 38865858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel molecular hybrids of EGCG and quinoxaline: Potent multi-targeting antidiabetic agents that inhibit α-glucosidase, α-amylase, and oxidative stress.
    Kothari M; Kannan K; Sahadevan R; Sadhukhan S
    Int J Biol Macromol; 2024 Apr; 263(Pt 1):130175. PubMed ID: 38360242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies.
    Asgari MS; Mohammadi-Khanaposhtani M; Kiani M; Ranjbar PR; Zabihi E; Pourbagher R; Rahimi R; Faramarzi MA; Biglar M; Larijani B; Mahdavi M; Hamedifar H; Hajimiri MH
    Bioorg Chem; 2019 Nov; 92():103206. PubMed ID: 31445191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyramine Derivatives as Potent Therapeutics for Type 2 Diabetes: Synthesis and
    Bashir MA; Javaid K; Shaikh M; Choudhary MI; Siddiqui H
    Med Chem; 2020; 16(8):1124-1135. PubMed ID: 32003674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and in vitro evaluation of chlorogenic acid amides as potential hypoglycemic agents and their synergistic effect with acarbose.
    Cardullo N; Floresta G; Rescifina A; Muccilli V; Tringali C
    Bioorg Chem; 2021 Dec; 117():105458. PubMed ID: 34736132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel 6-(piperidin-1-ylsulfonyl)-2H-chromenes targeting α-glucosidase, α-amylase, and PPAR-γ: Design, synthesis, virtual screening, and anti-diabetic activity for type 2 diabetes mellitus.
    Thabet HK; Abusaif MS; Imran M; Helal MH; Alaqel SI; Alshehri A; Mohd AA; Ammar YA; Ragab A
    Comput Biol Chem; 2024 Aug; 111():108097. PubMed ID: 38772048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of new clioquinol derivatives as potent α-glucosidase inhibitors; molecular docking, kinetic and structure-activity relationship studies.
    Wali S; Atia-Tul-Wahab ; Ullah S; Khan MA; Hussain S; Shaikh M; Atta-Ur-Rahman ; Choudhary MI
    Bioorg Chem; 2022 Feb; 119():105506. PubMed ID: 34896920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel carbazole-oxadiazole derivatives as anti-α-glucosidase and anti-α-amylase agents: Design, synthesis, molecular docking, and biological evaluation.
    Luo S; Zhao L; Peng H; Peng Z; Wang G
    Eur J Med Chem; 2024 Sep; 275():116600. PubMed ID: 38889608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New phenylthiosemicarbazide-phenoxy-1,2,3-triazole-N-phenylacetamides as dual inhibitors against α-glucosidase and PTP-1B for the treatment of type 2 diabetes.
    Ansariashlaghi S; Fakhrioliaei A; Mohammadi-Khanaposhtani M; Noori M; Asadi M; Mojtabavi S; Faramarzi MA; Esfahani EN; Rastegar H; Larijani B; Azizian H; Mahdavi M
    Arch Pharm (Weinheim); 2024 Jul; 357(7):e2300517. PubMed ID: 38593290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.